Breaking Research News from Breastcancer.org
Comments
-
Hormone Replacement Therapy’s Risks Are Complex
November 7, 2013
Long-term follow-up from the Women’s Health Initiative suggests that the link between combination hormone replacement therapy and higher breast cancer risk persists, but estrogen-only HRT may lower breast cancer risk. Read more...0 -
Radiation to Axillary Lymph Nodes Causes Less Lymphedema Than Surgery
November 7, 2013
A study has found that women diagnosed with early-stage breast cancer are less likely to have lymphedema if they get radiation to their axillary lymph nodes instead of having them surgically removed. Read more...0 -
More Evidence That Exercise, Including Walking, Reduces Risk
November 7, 2013
A large study done by the American Cancer Society has found that regular exercise at a moderate intensity level, such as walking, reduces breast cancer risk in postmenopausal women. Read more...0 -
My understanding is abraxane causes worse neuropathy than taxol!
0 -
Sentinel Lymph Node Surgery Not Appropriate for All Women Diagnosed With Breast Cancer
November 18, 2013
Research suggests that women diagnosed with breast cancer that is node-positive after being treated with chemotherapy before surgery aren’t good candidates for sentinel lymph node dissection because of high false-negative rates. Read more...0 -
Can Multivitamins With Minerals Offer Benefits to Diagnosed Women?
November 19, 2013
A study suggests that taking a multivitamin with minerals may benefit postmenopausal women diagnosed with breast cancer. Read more...0 -
Older Women May Have Higher Risk of Heart Problems From Herceptin
November 19, 2013
Older women diagnosed with early-stage, HER2-positive breast cancer treated with Herceptin seem to have a higher risk of heart failure than similar women who aren’t treated with Herceptin. Read more...0 -
Is a sentinel node biopsy ever done prior to neoadjuvant chemo? Wouldn't this be most accurate?0 -
Giving Herceptin and Anthracycline Chemotherapy at Same Time Offers No Extra Benefits
December 2, 2013
A study found that giving Herceptin at the same time as an anthracycline chemotherapy medicine before surgery for HER2-positive breast cancer doesn’t offer more benefits than giving Herceptin after an anthracycline. Read more...0 -
Studies Show Risks and Benefits of Intraoperative Radiation Therapy
December 3, 2013
While two large studies suggest that intraoperative radiation therapy offers about the same overall survival and rates as whole-breast external beam radiation therapy for certain women diagnosed with early stage-breast cancer, there are concerns about local recurrence rates. Read more...0 -
Modern Radiation Therapy Less Risky for Heart
December 9, 2013
A research letter estimates that modern radiation therapy techniques are less likely to cause heart problems than radiation therapy techniques used 20 or more years ago. Read more...0 -
FDA Tells 23andMe to Stop Marketing Test
December 9, 2013
The FDA has told 23andMe, a personal genetics company, that it must stop marketing its product because it hasn’t been approved. Read more...0 -
3-D Mammograms Find More Cancers and Reduce Call-Back Rates
December 9, 2013
A study suggests that 3-D mammography finds more breast cancers and leads to fewer call backs than conventional 2-D mammography. Read more...0 -
As part of our NEW podcast program, we're excited to bring you our premier podcast: a summary of yesterday's research highlights from the San Antonio Breast Cancer Symposium 2013! Breastcancer.org medical advisor Brian Wojciechowski, M.D. and senior editor Jamie DePolo explain the latest news. Listen to the December 11, 2013 podcast. -- approximately 25 minutes long.0 -
In this edition, we fill you in on the latest research about Arimidex (chemical name: anastrazole) for reducing the risk of a primary breast cancer, sticking to your aromatase inhibitor regimen, strength training and aerobics for the relief of aromatase inhibitor-induced joint pain relief, and survival improvements with bisphosphonates after early breast cancer. Breastcancer.org medical advisor Brian Wojciechowski, M.D. and senior editor Jamie DePolo explain the latest news. Listen to the December 12, 2013 podcast.
Running time: 27:160 -
In the December 13, 2013 edition
of our podcast coverage from the 2013 San Antonio Breast Cancer
Symposium, we bring you the latest information from these areas of
breast cancer research:- post-treatment psychosocial and physical issues
- updates on chemotherapy in high-risk women, early and metastatic
breast cancers, triple-negative breast cancers, and in women with high
numbers of circulating tumor cells - a new design for clinical trials that may allow drugs to become available sooner
- breast cancer incidence in women using hormonal treatments for infertility
- a presentation on what women know about risk reduction versus how
they put this knowledge into practice, from Breastcancer.org founder and
president Marisa Weiss, M.D.
Running time: 24:180 -
Pathologic Complete Response to Targeted Therapy Treatment Before Surgery Linked to Better Outcomes for HER2-Positive, Early-Stage Disease
January 15, 2014
The latest results from an on-going study suggest that pathologic complete response after Herceptin and Tykerb given before surgery to treat early-stage, HER2-positive, hormone-receptor-negative breast cancer is linked to better outcomes. Read more…0 -
Arimidex Helps Reduce Risk in High-Risk Postmenopausal Women
January 15, 2014
Arimidex lowers the risk of breast cancer in high-risk postmenopausal women who’ve never been diagnosed. Read more…0 -
Experimental Medicine Plus Carboplatin Helps Treat Triple-Negative Disease
January 22, 2014
The experimental therapy veliparib plus carboplatin followed by traditional chemotherapy before surgery for triple-negative breast cancer offers more benefits than traditional chemotherapy alone before surgery. Read more…0 -
Research Pinpoints Which Women Benefit From Bisphosphonates After Early-Stage Disease
January 28, 2014
A large study has found that bisphosphonates reduce the risk of distant breast cancer recurrence in postmenopausal women. Read more...0 -
Some Older Women With Hormone-Receptor-Positive Disease May Be Able to Skip Radiation After Lumpectomy
January 28, 2014
Research suggests that recurrence rates among women 65 and older
diagnosed with early-stage, hormone-receptor-positive disease who are
taking hormonal therapy are low; some of these women may be able to skip
radiation after lumpectomy. Read more...0 -
Exercise Reduces Joint Pain Caused by Aromatase Inhibitors
January 31, 2014
A new study has found that exercise eases joint pain that’s a common side effect of aromatase inhibitors. Read more...0 -
High Levels of Immune Cells in Breast Tumors May Predict How Cancers Respond to Treatments
January 31, 2014
Research suggests that breast cancer tumors with high levels of
tumor-infiltrating lymphocytes respond better to certain treatments,
including Herceptin and carboplatin. Read more...0 -
Another Look at Data Finds Mammography Benefits More Consistent Than Reported
January 31, 2014
Research shows that the benefits of screening mammograms are more
consistent studies than has been previously reported and that almost all
studies show a sizable reduction in deaths from breast cancer because
of screening mammograms. Read more...0 -
Avastin Doesn’t Help Treat HER2-Positive Breast Cancer
February 7, 2014
Another study found that adding Avastin to a regimen of Herceptin and
standard chemotherapy didn’t improve the outcomes of women diagnosed
with HER2-positive breast cancer. Read more...0 -
Women Taking Generic Aromatase Inhibitors More Likely to Stick to Treatment Plan
February 7, 2014
A study found that women taking generic aromatase inhibitors are more
likely to stick to their treatment plans compared to women taking
brand-name aromatase inhibitors. Read more...0 -
Women Who Have Aromatase Inhibitor Side Effects Before Starting Medicine Less Likely to Finish Therapy
February 7, 2014
Research suggests that women who are having side effects commonly
associated with aromatase inhibitors BEFORE they start taking an
aromatase inhibitor are much more likely to stop taking the medicine
early. Read more...0 -
Herceptin Plus Taxol Seems to Reduce Recurrence Risk of Small HER2-Positive Cancers
February 7, 2014
A small, early study suggests that a combination of Herceptin and Taxol
seemed to reduce the risk of recurrence of small HER2-positive breast
cancers that hadn’t spread to the lymph nodes. Read more...0 -
Study Looks at Women’s Awareness of Breast Cancer Risk Factors
February 12, 2014
Research looking at women’s awareness of the factors that lower breast
cancer risk suggests that women know what these risk-lowering factors
are, but don’t actually make the lifestyle changes required. Read more...0 -
Carboplatin
Shows Promise, But Adding Avastin to Standard Chemo Before Surgery Adds
More Severe Side Effects in Women Diagnosed With Triple-Negative
Disease
February 13, 2014
Research suggests adding Avastin to standard chemotherapy before surgery
increased the number of severe side effects in women diagnosed with
early-stage triple-negative breast cancer; adding carboplatin seemed to
offer benefits. Read more...0
